No abstract

Introduction A cholesteatoma is a three-dimensional sac lined by keratinized squamous epithelium containing desquamated keratinized epithelial cell which secretes enzymes that have the tendency to expand and erode the bony structure underlying it and cause intracranial and extracranial complications. This cystic mass is in an abnormal location such as the middle ear, the petrous apex, or the external auditory canal (EAC). It is mostly found in the middle ear and rarely in the EAC. Here we have reported a rare case of unilateral primary EAC cholesteatoma with mild hearing loss in a middle-aged male. Case Report We have reported a case of a 34-year-old male with complaints of right-sided ear discharge and right-sided decreased hearing for the last 5 to 6 years. On examination, right ear EAC was found to be dry, and a sac was observed in posterior wall extending to mastoid present with clear attic, and intact retracted tympanic membrane that was then followed by radiological evaluation to establish the diagnosis of EAC cholesteatoma. This was surgically treated and ear was cleared of all disease. Patient's symptoms improved postoperatively. Conclusion Primary EAC cholesteatoma with disease-free middle ear is a rare finding and there is very less definitive literature available on the pathogenesis of the same.

<p class="abstract"><strong>Background: </strong>Severe acute respiratory syndrome coronavirus-2 (SARS COV-2) infection has caused a global pandemic that has spread like wildfire throughout the world over a very short period of time. Though it may present with a multitude of symptoms mainly respiratory; neurological symptoms like smell and taste disturbances have emerged with greater frequency and sometimes as the only presentation in mild and moderate cases.</p><p class="abstract"><strong>Methods: </strong>This study was conducted at a tertiary hospital dedicated to COVID care in Northern India. Approval was sought from the Institutional Ethics Committee before the commencement of the study. Appropriate written and informed consent was obtained from all patients before their induction. All confirmed COVID -19 patients, previously documented to have chemosensory deficits of anosmia and dysgeusia over 3 months were followed up by over a period of 8 weeks. Data was collected on the basis of a comprehensive questionnaire telephonically at intervals of 2 weeks and 8 weeks and recorded.</p><p class="abstract"><strong>Results: </strong>During the period of study, from a sample of 450 patients, a total of 199 patients complained of chemosensory dysfunction out of which 63.8% were males (Figure 1). A total of 145 patients had dysgeusia and 136 had anosmia with a male preponderance of 62% and 63.9% respectively.</p><p class="abstract"><strong>Conclusions: </strong>Residual post-COVID symptoms last and whether they may permanently affect quality of life further studies are required.</p>